Drug intelligence / Profile preview

BIO-008

Development stage: Phase 1
Lead developer: Yiling Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BIO-008 is a monoclonal antibody developed by Shijiazhuang Yiling Pharmaceutical for the treatment of advanced solid tumors. Its mechanism of action involves targeting Claudin-18.2 (CLDN18.2), a tight junction protein overexpressed in certain cancers, including gastric cancer, gastroesophageal junction cancer, and pancreatic cancer. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity in patients with advanced or metastatic solid tumors that express CLDN18.2[1][2][4]. The primary indications under investigation are advanced gastric cancer or gastroesophageal junction cancer and pancreatic cancer[1].

Targets

Claudin 18.2

Beyond the preview

Go deeper on BIO-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIO-008.

Explore the full profile